Potential implications of the new pharmacotherapies on obesity management The mean WL in clinical trials with the most efficacious new obesity pharmacotherapies ranges between 15% and 25% at 1 year (and it may be even higher for some agents that have not reached weight plateau at study completion)
Patients with documented gallstones should discuss with their healthcare team whether to continue semaglutide, as the decision depends on individual circumstances including symptom severity, weight loss goals, glycemic control needs, and surgical candidacy
While oral B12 supplements can be effective, B12 injections are often more potent and provide faster results, especially for individuals with vitamin absorption issues
observed that ISL mitigated NAFLD/NASH symptoms by downregulating SREBP and upregulating PPAR activities via the IQGAP2-CREB-SIRT1 axis (Zhang et al., 2021)
Disruption of this cycle can have far-reaching effects on cellular function, gene expression, and neurodevelopment
The headline read: EASO, as a scientific society, gives semaglutide and tirzepatide a high ranking, positioning them at the forefront of the fight against obesity